Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26232024 | 0.95 | TLR2 (0.45) | TLR2MDM2PTPN1 | |
| SCHEMBL31648943 | 0.95 | TLR2 (0.45) | TLR2MDM2PTPN1 | |
| SCHEMBL29716733 | 0.95 | TLR2 (0.45) | TLR2MDM2PTPN1 | |
| SCHEMBL31631998 | 0.95 | TLR2 (0.45) | TLR2MDM2PTPN1 | |
| SCHEMBL31557564 | 0.90 | TLR2 (0.46) | TLR2MDM2KMT2APTPN1 | |
| SCHEMBL16757656 | 0.90 | TLR2 (0.46) | TLR2MDM2KMT2APTPN1 | |
| SCHEMBL16757654 | 0.90 | TLR2 (0.46) | TLR2MDM2KMT2APTPN1 | |
| SCHEMBL29358858 | 0.90 | TLR2 (0.46) | TLR2MDM2PTPN1MDM4TP53 | |
| SCHEMBL17322760 | 0.90 | TLR2 (0.47) | TLR2MDM2PTPN1 | |
| SCHEMBL29083314 | 0.90 | TLR2 (0.45) | TLR2MDM2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240026363-A1 | RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20170290925-A1 | Conjugates And Conjugating Reagents | POLYTHERICS LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | SOD1, SOD3, SMN1; SMN2 | TLR2 4072/4885MDM2 493/4885KMT2A 2125/4885 |
| US-20170290925-A1 | Conjugates And Conjugating Reagents | ANPEP, NGLY1, PCTP | TLR2 3035/4885MDM2 2441/4885KMT2A 3168/4885 |
| US-20240026363-A1 | RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use | SOD1, SOD3, SMN1; SMN2 | TLR2 4034/4885MDM2 480/4885KMT2A 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.